Form 4: Catalyst Pharmaceuticals' Chief Operating and Scientific Officer Reports Stock Transactions

Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, reports the vesting and delivery of restricted stock units, resulting in an increase in his holdings of common stock.

Summary

• On February 14, 2025, Steve Miller, the Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, had restricted stock units vest and convert into common stock.
• A total of 13,667 shares were acquired through the vesting of these restricted stock units.
• Following this transaction, Miller directly owns 949,663 shares of common stock and 1,524,509 derivative securities.
• The restricted stock units vested in equal tranches over three years, with the final tranche vesting on February 14, 2025.
• The shares of common stock related to the final vesting were delivered on February 14, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The vesting of restricted stock units and subsequent delivery of shares to a key executive could be seen as a positive sign of alignment between management and shareholder interests.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.

Stakeholder Impact

• The transaction has a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates